Inhibition of proliferation of cells

Details Inhibition of proliferation of cells Inhibition of proliferation of cells

1999-04-13

2001-03-13

Schwartzman, Robert A. (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C435S006120, C435S091100, C435S091310, C435S325000, C435S375000, C536S023100, C536S024300, C536S024500, C514S04400A

Reexamination Certificate

active

06200960

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates to a method of inhibiting the activation of a gene which has in turn been shown to lead to the induction of a number of other genes that have been strongly implicated in the development of vascular disease such as atherosclerosis and restenosis. In addition, the present invention relates to oligonucleotides which can be used in this method. The invention seeks to inhibit the proliferation of cells, migration of cells to sites of injury and remodelling of vascular wall, associated with the pathogenesis of atherosclerosis or restenosis, such as smooth muscle cells or endothelial cells.
BACKGROUND OF THE INVENTION
Atherosclerosis is thought to originate from a subtle process of endothelial injury. Vascular endothelium constitutes a non-thrombogenic surface of normally quiescent cells that line blood vessels and regulate molecular and cellular movement across the vessel well. In response to denuding injury, endothelial cells at the wound edge spread and migrate into the vacant area, undergo proliferation and secrete factors that stimulate endothelial and smooth muscle cell growth. These responses provide an important homeostatic mechanism for maintaining normal vascular function. Growth factors such as platelet-derived growth factor (PDGF, which comprises an A chain and/or a B chain) and basic fibroblast growth factor (bFGF) have been implicated to play key roles in the regenerative events following vascular injury. The induction of PDGF gene expression in vascular endothelium may have profound chemotactic and mitogenic effects on the underlying smooth muscle cells and contribute to the structural remodelling that typically occurs in experimental arterial repair, restenosis and in the pathogenesis of atherosclerotic vascular disease (1). Smooth muscle cells are found in both fatty streaks and fibrous atherosclerotic plaques. Their proliferation and ability to form enormous amounts of connective tissue matrix and accumulate lipid are key contributing factors in the development of the atherosclerotic lesion.
Despite a wealth of descriptive studies which correlate the formation of vascular occlusive lesions with the inappropriate expression of these and other growth regulatory molecules (2), a direct link between a transcription factor and the induced expression of a pathophysiologically relevant gene has not yet been demonstrated in the context of arterial injury.
The treatment of occluded coronary arteries currently involves the use of percutaneous transluminal coronary angioplasty (PCTA) or more recently PCTA in conjunction with the placement of a device known as a stent. PCTA is a balloon device that is delivered to the affected site via a catheter and following expansion of the balloon results in physical removal of the blocking plaque or thrombus and enlargement of the local vessel area.
The application of the stent, a fenestrated metallic sleeve, adds additional support to the re-opened vessel and amongst other benefits, prevents the frequency of elastic recoil of the vessel wall. In some of the cases of intervention the benefit of the treatment is short lived and the vessel undergoes reclosure or restenosis. Restenosis is a multi-phased clinical event and can involve elastic recoil in the first instance followed by extensive vascular remodelling and luminal shrinkage. The final stages of the restenotic process involve recruitment and proliferation of smooth muscle cells to create a neo-intimal mass between the elastic lamina and the endothelium. The incidence of restenosis has gradually reduced with the advancement of healthcare methods but is still a significant problem (Kimura et al. (1996) New England Journal of Medicine 335:561-566, Bittl, (1996) New England Journal of Medicine 334:1290-1302).
There is considerable activity focussed on the development of pharmaceuticals to be used as adjuncts to the interventional methods in an attempt to reduce the incidence of restenosis. Some of the classes of drugs under development include:
(a) Anticoagulants—agents such as hirudin and bivalirudin target the formation of thrombin rich clots.
(b) Antiplatelet drugs—suppression of platelet activation can reduce the formation of platelet aggregates and clotting. One approach involves the use of a monoclonal antibody dubbed Abciximab that is specific for the platelet fibrinogen receptor glycoprotein IIb/IIIa.
(c) Antiproliferatives—Trapidil is an antagonist of the PDGF receptor. PDGF is an established stimulator of smooth muscle cell recruitment and proliferation and it is proposed that inhibition of PDGF activity will inhibit this activity.
(d) Antioxidants—compounds such as Probucal are currently under investigation as agents to remove oxidative stress from vessel walls and thus limit the smooth muscle cell proliferation associated with such stress.
(e) Nucleic acid based therapies—antisense and ribozymes directed against specific targets e.g. WO 96/25491, WO 96/20279 and WO 96/11266
SUMMARY OF THE INVENTION
It has been found that Egr-1 is rapidly activated following arterial injury. Induced Egr-1 binds to, and stimulates expression from, the control regions of several genes whose products cause cell proliferation, cell recruitment and vascular wall remodelling of vascular cells.
Accordingly, in a first aspect, the present invention consists in a method of inhibiting proliferation of cells comprising inhibiting induction or decreasing expression of Egr-1 or decreasing the nuclear accumulation or activity of the Egr-1 gene product.
In a preferred embodiment the cells are vascular cells, particularly smooth muscle or endothelial cells. The cells may, however, be cells involved in neoplasia.
As will be recognised by those skilled in this field there are a number means by which the method of the present invention may be achieved. These include the following:
(a) Targeting the Egr-1 gene directly using triple helix (triplex) methods in which a ssDNA molecule can bind to the dsDNA and prevent transcription.
(b) Inhibiting transcription of the Egr-1 gene using nucleic acid transcriptional decoys. Linear sequences can be designed that form a partial intramolecular duplex which encodes a binding site for a defined transcriptional factor. Evidence suggests that Egr-1 transcription is dependent upon the binding of Sp1. AP1 or serum response factors to the promoter region. It could be envisaged that inhibition of this binding of one or more of these transcription factors would inhibit transcription of the Egr-1 gene.
(c) Inhibition of translation of the Egr-1 mRNA using synthetic antisense DNA molecules that do not act as a substrate for RNase H and act by sterically blocking gene expression.
(d) Inhibition of translation of the Egr-1 mRNA by destabilising the mRNA using synthetic antisense DNA molecules that act by directing the RNase H-mediated degradation of the Egr-1 mRNA present in the heteroduplex formed between the antisense DNA and mRNA.
(e) Inhibition of translation of the Egr-1 mRNA by destabilisation of the Egr-1 mRNA by cleavage of the mRNA by sequence-specific hammerhead ribozymes and derivatives of the hammerhead ribozyme such as the Minizymes or Mini-ribozymes or where the ribozyme is derived from:
(i) the hairpin ribozyme,
(ii) the Tetrahymena Group I intron,
(iii) the Hepatitis Delta Viroid ribozyme or
(iv) the Neurospera ribozyme.
The composition of the ribozyme could be:
(i) made entirely of RNA,
(ii) made of RNA and DNA bases,
or
(iii) made of RNA or DNA and modified bases, sugars and backbones
The ribozyme could also be either:
(i) entirely synthetic or
(ii) contained within a transcript from a gene delivered within a virus-derived vector, expression plasmid, a synthetic gene, homologously or heterologously integrated into the patients genome or delivered into cells ex vivo, prior to reintroduction of the cells of the patient, using one of the above methods.
(f) Inhibition of translation of the Egr-1 mRNA by cleavage of the mRNA by sequence-specific catalytic molecules composed of DNA. For example molecules described previo

Affiliated with

Also associated with

Rating

Inhibition of proliferation of cells does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibition of proliferation of cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of proliferation of cells will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2525767